• Something wrong with this record ?

Functionalized nanoliposomes loaded with anti survivin and anti angiogenic agents to enhance the activity of chemotherapy against melanoma by 4-pronged action

H. Mishra, PK. Mishra, A. Ekielski, Z. Iqbal, M. Jaggi, S. Talegaonkar,

. 2018 ; 116 (-) : 141-146. [pub] 20180508

Language English Country United States

Document type Journal Article

Persistent link   https://www.medvik.cz/link/bmc19000680

Melanoma is one of the most aggressive cancers which has very low response rate and survival rate. Melanoma cells are known to be inherently resistant to the chemotherapy which results in poor outcomes and even failure of the therapy. For this reason, a better understanding of underlying mechanism of melanoma pathogenesis and resistance is required, so that more efficient and novel therapeutic strategies can be developed. Survivin is a protein which is overexpressed in melanoma cells and is known to impart resistance to them against apoptosis. Also, melanoma cells overexpress Vascular Endothelial Growth Factor (VEGF) and basic Fibroblast Growth Factor (bFGF) angiogenic growth factors which lead to aggressive angiogenesis in melanoma cells thereby making the treatment more challenging. This hypothesis presents a combinatorial approach against melanoma where an anti-survivin agent and an anti-angiogenic agent are combined with a chemotherapeutic drug and loaded in surface functionalized liposomes in order to target specific mechanisms of melanoma, thus overcoming its resistance. Thus, the study aims to overcome the resistance of melanoma cells by developing a wise combination of drugs and achieve a higher response rate in resistant melanoma model, which is usually not achieved with the existing treatment modalities.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc19000680
003      
CZ-PrNML
005      
20200121143240.0
007      
ta
008      
190107s2018 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.mehy.2018.05.002 $2 doi
035    __
$a (PubMed)29857900
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Mishra, Harshita $u Dept. of Pharmaceutics, School of Pharmaceutical Education and Research, Jamia Hamdard, New Delhi, India.
245    10
$a Functionalized nanoliposomes loaded with anti survivin and anti angiogenic agents to enhance the activity of chemotherapy against melanoma by 4-pronged action / $c H. Mishra, PK. Mishra, A. Ekielski, Z. Iqbal, M. Jaggi, S. Talegaonkar,
520    9_
$a Melanoma is one of the most aggressive cancers which has very low response rate and survival rate. Melanoma cells are known to be inherently resistant to the chemotherapy which results in poor outcomes and even failure of the therapy. For this reason, a better understanding of underlying mechanism of melanoma pathogenesis and resistance is required, so that more efficient and novel therapeutic strategies can be developed. Survivin is a protein which is overexpressed in melanoma cells and is known to impart resistance to them against apoptosis. Also, melanoma cells overexpress Vascular Endothelial Growth Factor (VEGF) and basic Fibroblast Growth Factor (bFGF) angiogenic growth factors which lead to aggressive angiogenesis in melanoma cells thereby making the treatment more challenging. This hypothesis presents a combinatorial approach against melanoma where an anti-survivin agent and an anti-angiogenic agent are combined with a chemotherapeutic drug and loaded in surface functionalized liposomes in order to target specific mechanisms of melanoma, thus overcoming its resistance. Thus, the study aims to overcome the resistance of melanoma cells by developing a wise combination of drugs and achieve a higher response rate in resistant melanoma model, which is usually not achieved with the existing treatment modalities.
650    _2
$a inhibitory angiogeneze $x chemie $7 D020533
650    _2
$a protinádorové látky $x chemie $7 D000970
650    _2
$a proliferace buněk $7 D049109
650    _2
$a dakarbazin $x terapeutické užití $7 D003606
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a fibroblastový růstový faktor 2 $x metabolismus $7 D016222
650    _2
$a lidé $7 D006801
650    _2
$a antigeny CD44 $x metabolismus $7 D018960
650    _2
$a inhibitory apoptózy $x chemie $7 D051034
650    _2
$a liposomy $x chemie $7 D008081
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a melanom $x metabolismus $x terapie $7 D008545
650    _2
$a teoretické modely $7 D008962
650    _2
$a nanočástice $x chemie $7 D053758
650    _2
$a patologická angiogeneze $7 D009389
650    _2
$a nádory kůže $x terapie $7 D012878
650    _2
$a survivin $7 D000077022
650    _2
$a vaskulární endoteliální růstový faktor A $x metabolismus $7 D042461
655    _2
$a časopisecké články $7 D016428
700    1_
$a Mishra, Pawan Kumar $u Dept. of Wood Processing, Mendel University, Brno, Czech Republic.
700    1_
$a Ekielski, Adam $u Department of Production Management and Engineering, Warsaw University of Life sciences, Poland.
700    1_
$a Iqbal, Zeenat $u Dept. of Pharmaceutics, School of Pharmaceutical Education and Research, Jamia Hamdard, New Delhi, India.
700    1_
$a Jaggi, Manu $u Dabur Research Foundation, Ghaziabad, India.
700    1_
$a Talegaonkar, Sushama $u Dept. of Pharmaceutics, School of Pharmaceutical Education and Research, Jamia Hamdard, New Delhi, India; DPSRU, New Delhi, India. Electronic address: stalegaonkar@jamiahamdard.ac.in.
773    0_
$w MED00003234 $t Medical hypotheses $x 1532-2777 $g Roč. 116, č. - (2018), s. 141-146
856    41
$u https://pubmed.ncbi.nlm.nih.gov/29857900 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20190107 $b ABA008
991    __
$a 20200121143617 $b ABA008
999    __
$a ok $b bmc $g 1363895 $s 1038803
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2018 $b 116 $c - $d 141-146 $e 20180508 $i 1532-2777 $m Medical hypotheses $n Med Hypotheses $x MED00003234
LZP    __
$a Pubmed-20190107

Find record

Citation metrics

Archiving options